Site Content
akttyva opens new laboratories in Watertown
November 1, 2024 Akttyva Therapeutics opened a new office and laboratory at 155 Arlington Street, Watertown, MA 02472 within Cambridge Scientific incubator. Moving into the greater Boston area allows the Company to have better access to the talent and become a part of the Cambridge / Boston biotech community. The space is located on the Charles River bike path and near Cambridge with all major universities and companies within minutes of the new Company headquarters.
David bowman joins akttyva as a ceo
September 24, 2024 Akttyva Therapeutics is excited to announce that David Bowman, Ph.D., an experienced tech entrepreneur with the 30+ years experience in software and a history of successful product development in a wide range of industries joins Akttyva as an interim Chief Executive Officer. David will continue building the team and lead the company going forward. David's experience in start-ups, software products development, fund-raising and pioneering work in applying machine learning, neural networks and AI are a perfect fit for Akttyva.
Akttyva gets NSF phase 2 award
August 15, 2024 Akttyva Therapeutics was awarded a highly competitive National Science Foundation Phase 2 Award. The $1,000,000 funding serves as an independent government agency validation of the science behind Akttyva's programs and allows the Company to continue building its pipeline using the proprietary AI-powered drug-discovery platform AIDE360.
Yosef Landesman joins Akttyva
September 1, 2023 We are excited to announce that Dr. Yosef Landesman has joined Akttyva's team as a Drug Discovery and Translational Research Advisor. Dr. Landesman brings over 20 years of translational drug-discovery experience with taking drugs from discovery through all stages of development and to the market at Karyopharm and making crucial contributions as a Chef Scientific Officer at HC Biosciences and Alnylam.
Akttyva Therapeutics gets NSF award
December 14, 2021 Honored to announce a National Science Foundation (NSF) award to further develop and commercialize our AIDE-360 platform that aims at facilitating the rational design of therapeutics addressing vascular leak disorders. This highly competitive award is a demonstration of innovative nature and commercial potential, the two main criteria for NSF grant review. This grant will allow us to accelerate the 2nd generation AIDE-360 and develop the commercialization plan. More about the program: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136307&HistoricalAwards=false
akttyva won an ibm prize
November 17, 2021. Akttyva Therapeutics won an IBM prize for its AI drug-discovery program AIDE-360, which was used to discover the hits for the vascular leak program
Akttyva is a finalist of masschallenge
October 1, 2021. Akttyva Therapeutics is a finalist of the highly selective 2021 MassChallenge competition! We are honored to be one of only 45 companies out of 229 selected for the final round (out of over 3,000 original applications). The winners of the final round will compete for $1M non-dilutive cash prizes competition
akttyva opens laboratories
April 1, 2021 Akttyva has established laboratories in Mansfield Bioincubator
Dr. Mario dipaola joins the team
January 10, 2021 Dr. Mario DiPaola, an experienced scientist and successful entrepreneur, joins Akttyva as Head of Research.
Site Content
akttyva opens laboratories
April 1, 2021 Akttyva has established laboratories in Mansfield Bioincubator
Dr. Mario dipaola joins the team
January 10, 2021 Dr. Mario DiPaola, an experienced scientist and successful entrepreneur, joins Akttyva as Head of Research.